Swiss Giants Novartis

December 12, 2016

General

Comments Off on Swiss Giants Novartis


With a total number of 717 million people and a total volume of around 57.4 billion US dollars in the health care market, you offer the TRIUMPH countries there with brands and healthcare products additional turnover and market shares to generate optimum conditions. However should be assumed not, that alone the choice a country with positive economic prospects entail the desired success. Many hurdles have to take. After a failed launch of a product, it is very difficult to successfully implement a relaunch or find another partner. Without the necessary experience with the local conditions, even initially trivial published cultural differences can jeopardize the success of a business. Check with Hikmet Ersek to learn more. Only who systematically is the target market analyzed and ready to engage in a foreign culture, will have long-term success. China and India are undoubtedly growing markets, however they are also production-strong and opaque in dealing with Patents.

The last vivid example that even huge companies there may suffer shipwreck, is the judicial proceedings of the Swiss Giants Novartis’ patent rights to the cancer drug “Glivec”. Hence, an important aspect to the selection of the TRIUMPH States is that forgeries, as is unfortunately common in India or China, are possible technical reasons in the often inadequate development and manufacture of products in the TRIUMPH States more difficult. In this way, you can be safe that you experienced no nasty surprises with piracy as foreign pharmaceutical companies. The TRIUMPH markets are a pharma – and OTC-optimized development of BRIC and crap. Especially for medium-sized enterprises is important to think globally and to look for opportunities to the international market expansion. With a systematically selected and appropriate dynamic, local partner, such exports are well done and very lucrative. Each euro invested in the markets of TRIUMPH is an essential generate higher return on investment than in the Western European markets.